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Takuya Umemoto, MD, PhD, Shizuoka, Japan
Purpose: It remains unclear whether population-based screening for abdominal aortic aneurysm (AAA) in men reduces
all-cause long-term mortality. We performed an updated meta-analysis of randomized controlled trials of AAA screening
for prevention of long-term mortality in men.
Methods: To identify all randomized controlled trials of population-based AAA screening with long-term (>10 year)
follow-up in men, MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials were searched through
June 2009. Data regarding AAA-related and all-cause mortality (including Cox regression hazard ratios [HRs] and 95%
confidence intervals [CIs]) were abstracted from each individual study. For each study, data regarding mortality in both
the screening and control groups were used to generate odds ratios (ORs) and 95% CIs. Study-specific estimates were
combined using inverse variance-weighted averages of logarithmic ORs orHRs (or risk ratios where noHRwas reported)
in both fixed- and random-effects models.
Results: Our search identified four randomized controlled trials of population-based AAA screening with long-term
follow-up in men aged >65 years. Pooled analysis demonstrated a statistically significant reduction in AAA-related
mortality (random-effects OR, 0.55; 95% CI, 0.36 to 0.86; P  .008; P for heterogeneity  .01; absolute risk reduction
[ARR], 4 per 1000; number needed to screen [NNS], 238; random-effects HR, 0.55; 95% CI, 0.35 to 0.86; P  .009;
P for heterogeneity  .009) and revealed a statistically nonsignificant reduction (but a strong trend toward a significant
reduction) in all-cause mortality (fixed-effects OR, 0.98; 95% CI, 0.95 to 1.00 [1.001]; P  .06; P for heterogeneity 
.93; ARR, 5 per 1000; NNS, 217; fixed-effects HR, 0.98; 95% CI, 0.96 to 1.00 [1.0001]; P > .05 [P  .052]; P for
heterogeneity  .74) with AAA screening relative to control.
Conclusion: The results of our analysis suggest that population-based screening for AAA reduces AAA-related long-term
mortality by 4 per 1000 over control in men aged >65 years. Whereas, screening for AAA shows a strong trend toward
a significant reduction in all-cause long-term mortality by 5 per 1000, which does not narrowly reach statistical
significance. (J Vasc Surg 2010;52:1103-8.)In a Cochrane systematic review by Cosford and Leng1
published in 2007, there was evidence of a significant
reduction in mortality from abdominal aortic aneurysm
(AAA) inmen aged 65 to 79 years who undergo ultrasound
screening, but no significant difference in all-cause mortal-
ity between screened and unscreened groups 3 to 5 years
after screening.Meanwhile, a more recent meta-analysis, by
Lindholt and Norman,2 published in 2008, of randomized
controlled trials, showed that population-based screening
for AAA reduced both AAA-related and all-cause long-
term (7-15 year) mortality. The results are very interesting,
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doi:10.1016/j.jvs.2010.02.283as a 3% all-cause mortality reduction is more than what
would be expected by an approximately 50% AAA-related
mortality reduction of a disease causing 1.5% to 3% of all
deaths among men aged 65 or more.3 Lederle3 and Ko-
elemay,4 however, revealed errors in the meta-analysis2 and
claimed that the reduction in all-cause mortality failed to
reach statistical significance. Furthermore, Lederle3 indi-
cated that previous meta-analyses, including ours,1,2,5-8
with the exception of a systematic review by Fleming et al9
for the US Preventive Services Task Force (USPSTF), had
made the same error of using age unadjusted deaths from
one of the randomized controlled trials (Western Australia
study10). In 2009, Thompson et al11 presented new infor-
mation from the 10-year follow-up in another randomized
controlled trial (Multicentre Aneurysm Screening Study
[MASS]). It remains unclear whether population-based
screening for AAA in men reduces all-cause long-term
mortality. We performed an updated meta-analysis of ran-
domized controlled trials of population-based AAA screen-
ing for prevention of long-term mortality in men.
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All randomized controlled trials of population-based
screening for AAA in men were identified using a two-level
search strategy. First, public domain databases including
MEDLINE, EMBASE, and Cochrane Central Register of
Controlled Trials were searched using Web-based search
engines (PubMed, OVID). Second, relevant studies were
identified through a manual search of secondary sources
including references of initially identified articles and a
search of reviews and commentaries. All references were
downloaded for consolidation, elimination of duplicates,
and further analysis. The MEDLINE and EMBASE data-
bases, and Cochrane Library and Central Register of Con-
trolled Trials were searched through June 2009. MeSH
keywords included mass screening, aortic aneurysm, abdo-
men, and randomized controlled trial. Exploding keywords
included screening, abdominal aortic aneurysm, and ran-
domized controlled trial. Studies considered for inclusion
met the following criteria: the design was a population-
based randomized controlled trial; the study population
was men; participants were randomly assigned to an invita-
tion to attend screening for AAA versus no invitation
(control); and main outcomes included long-term (10
year) mortality. All searches included only English-
language abstracts. Predefined criteria from the USPSTF
were used to assess the internal validity of each trial and to
assign quality ratings of “good,” “fair,” or “poor.”12 Qual-
ity criteria for randomized controlled trials included assem-
bly of comparable groups, maintenance of comparable
groups, important differential loss to follow-up or overall
high loss to follow-up, valid and reliable measurements,
clear definition of interventions, all important outcomes
considered, and intention-to-treat analysis. In general, a
good study meets all criteria, a fair study does not meet all
criteria but is judged to have no fatal flaw, and a poor study
contains a fatal flaw. Data regarding detailed inclusion
criteria, duration of follow-up, and AAA-related and all-
cause mortality (including Cox regression hazard ratios
[HRs] and 95% confidence intervals [CIs]) were abstracted
(as available) from each individual study. For each study,
data regarding mortality in both the invited and control
groups were used to generate odds ratios (ORs) and 95%
CIs. Where no HR was reported, we generated risk ratios
(RRs) instead of HRs using data regarding mortality.
Study-specific estimates were combined using inverse
variance-weighted averages of logarithmic ORs or HRs in
both fixed- and random-effects models. Between-study
heterogeneity was analyzed by means of standard chi
squared tests. Where no significant statistical heterogeneity
was identified, the fixed-effects estimate was used preferen-
tially as the summary measure. Publication bias was assessed
graphically using funnel plots and mathematically using a
linear regression test, according to the method of Egger et
al.13 All analyses were conducted using Review Manager
(RevMan) version 5.014 and Microsoft Excel 2004 version
11.5 (Microsoft, Redmond, Wash).RESULTS
Two authors (H.T. and T.U.) reviewed 134 abstracts
and 25 articles using defined inclusion criteria. Our search
identified four randomized controlled trials of population-
based screening for AAA with long-term follow-up in men
aged 65 years: 15-year results in the Chichester study
(men),15 10-year results in the MASS,11 14-year results in
the Viborg Country study,16 and 11-year results in the
Western Australia study.3 The MASS was rated as good
quality and the other three studies were done as fair quality
according to the USPSTF rating criteria.12 In the Chiches-
ter study (men), MASS, and Viborg Country study, ORs
for both AAA-related and all-cause deaths could be gener-
ated. In the Western Australia study, however, no OR for
AAA-related deaths could be generated, since no AAA-
related mortality was available. In the Chichester study
(men), MASS, and Viborg Country study, HRs for both
AAA-related and all-cause deaths were reported. In the
Western Australia study, however, no HR for both AAA-
related and all-cause deaths was reported. Since only all-
cause (not AAA-related) 11-year deaths (for men aged 65
to 74 years only) in the Western Australia study were cited
in the response to the comment by Lederle3 on the meta-
analysis by Lindholt and Norman,2 we generated an OR
and a RR (instead of a HR) for all-cause deaths. In total,
our meta-analysis included data based upon 114,376 par-
ticipants (men) randomized to an invitation to attend
screening for AAA (n  57,181) or no invitation (control;
n  57,195).
Pooled analysis of the three ORs (no OR for AAA-
related deaths was available in the Western Australia study)
demonstrated a statistically significant reduction in AAA-
related mortality (random-effects OR, 0.55; 95% CI, 0.36
to 0.86; P .008; P for heterogeneity .01; absolute risk
reduction [ARR], 4 per 1000; number needed to screen
[NNS], 238; Fig 1A), and pooled analysis of the 4 ORs
revealed a statistically nonsignificant reduction (but a
strong trend toward a significant reduction) in all-cause
mortality (fixed-effects OR, 0.98; 95% CI, 0.95 to 1.00
[1.001]; P  .06; P for heterogeneity  .93; ARR, 5 per
1000; NNS, 217; Fig 1B) with an invitation to screening
for AAA relative to control. Pooled analysis of the three
HRs (neither HR nor RR for AAA-related deaths was
available in the Western Australia study) demonstrated a
statistically significant reduction in AAA-related mortality
(random-effects HR, 0.55; 95%CI, 0.35 to 0.86; P .009;
P for heterogeneity .009; Fig 2A), and pooled analysis of
the three HRs and one RR (instead of HR) revealed a
statistically nonsignificant reduction (but a strong trend
toward a significant reduction) in all-cause mortality (fixed-
effects HR, 0.98; 95% CI, 0.96 to 1.00 [1.0001]; P  .05
[P  .052]; P for heterogeneity  .74; Fig 2B) with an
invitation to screening for AAA relative to control. To
assess publication bias, we generated funnel plots of the
logarithm of effect size versus the standard error for each
trial (data not shown). There was no evidence of significant
publication bias (P .97 for AAA-related ORs; P .27 for
interval; IV, inverse variance; MASS, Multicentre Aneurysm Screening Study.
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Fig 2. Meta-analysis of hazard ratios from randomized controlled trials of population-based abdominal aortic
aneurysm (AAA) screening for prevention of AAA-related (A) and all-cause (B) long-term mortality in men. CI,A
B
Fig 1. Meta-analysis of odds ratios from randomized controlled trials of population-based abdominal aortic aneurysm
(AAA) screening for prevention of AAA-related (A) and all-cause (B) long-term mortality in men. CI, ConfidenceConfidence interval; IV, inverse variance; MASS, Multicentre Aneurysm Screening Study; SE, standard error.
JOURNAL OF VASCULAR SURGERY
October 20101106 Takagi et alall-cause ORs; P  .97 for AAA-related HRs; P  .30 for
all-cause HRs; by Egger linear regression test).
DISCUSSION
The results of our analysis suggest that population-
based screening for AAA reduces AAA-related long-term
mortality by 4 per 1000 over control in men aged 65
years. Whereas, screening for AAA shows a strong trend
toward a significant reduction in all-cause long-term mor-
tality by 5 per 1000, which does not narrowly reach statis-
tical significance. Since AAA-related deaths account for
only a small proportion (2.61% in the included studies) of
all-cause deaths, the reduction in AAA-related mortality
may not directly contribute toward the reduction in all-
cause mortality. The mortality data used suffer the inevita-
ble inaccuracy associated with lack of post-mortem confir-
mation.17 Deaths outside hospital may have been
misclassified; the sudden death of a man with known a small
AAA might risk misclassification as due to the aneurysm.18
Cases with rupture of an unknown aneurysm risk being
misclassified as cardiac disease because of the high preva-
lence of coexisting cardiac morbidity. Both types of mis-
classification would lead to an underestimation of the ben-
efits of screening for AAA.18
In the MASS, blood pressure and pulse were taken
three times on arrival at screening, and the median blood
pressure was reported to the family doctor.19 In the Viborg
Country study, smokers with AAA were advised to stop
smoking, and patients with substandard management of
high blood pressure were advised to consult their doctor.18
In the Western Australia study, each man was given a letter
containing the results of his scan, with a copy for his general
practitioner.10 The general practitioner arranged any follow-
up investigations, though the study investigators made no
attempt to influence any aspects of clinical management.
Mastracci and Cinà hypothesized, in their reply to our
Letter to the Editor7 regarding their review article,20 that a
reduction in lifestyle-related cardiovascular risk factors,
which were addressed when the participants accessed med-
ical care for screening, might decrease all-cause mortality
in the screened population. If the hypothesis is valid,
nonaneurysm-related deaths are distributed in attenders for
screening less than in nonattenders for screening or in
uninvited controls. Our previous pooled analysis8 of the
four randomized controlled trials demonstrated a stat-
istically significant reduction in mid-term (3-5 year)
nonaneurysm-related mortality with attenders for screen-
ing (9.73%) relative to nonattenders for screening (17.46%;
OR, 0.50; 95% CI, 0.48 to 0.53; ARR, 79 per 1000).
Attenders for screening was associated with a statistically
significant reduction in mid-term nonaneurysm-related
mortality relative to uninvited controls (12.37%; OR,
0.77; 95% CI, 0.65 to 0.90; ARR, 26 per 1000). Fewer
nonaneurysm-related deaths in attenders for screening may
be a result of lifestyle changes (diet, smoking, and exercise)
among participants who were screened (although no spe-
cific advice was given) or treatment of high blood pressure
given by the family physician after measurements takenwith the scan.21 Another explanation could be that people
who refuse screening are older and would be expected to
include a high proportion of those unwell from other
causes.17 On the contrary, however, participants who ac-
cepted the invitation may have been more conscious of
those risk factors predisposing to all-cause mortality. It is
unclear in long-term follow-up whether or not the hypoth-
esis is valid, since only two studies (Chichester study
[men]15 and Viborg Country study22) reported long-term
nonaneurysm-related mortality separately in attenders and
nonatternders for screening. In the 10-year results in the
MASS,11 although fewer deaths from ischemic heart dis-
ease occurred in the invited group, this difference was not
statistically convincing, and the mean age of the men who
died was 74.7 in both groups. These findings may not
suggest any major general differences in health care be-
tween the groups as a result of screening.11
In the meta-analysis by Lindholt and Norman2 and the
comments (Letters to the Editor) by Lederle3 and Ko-
elemay4 on the meta-analysis, there was a lot of confusion
regarding citation of all-cause mortality from original arti-
cles of the randomized controlled trials. The confusion was
summarized in the Table. In the present meta-analysis, we
resolved all the confusion and updated the results of the
MASS and Viborg Country study (adding approximately
10,000 new deaths), resulting in a strong trend toward
significant reduction in all-cause mortality.
Previous meta-analyses of population-based screening
for AAA combined ORs1,2,5,9 or risk differences6-8 for
deaths. The most appropriate way of summarizing time-to-
event (survival) data, however, is to use methods of survival
analysis and express the intervention effect as an HR, which
is interpreted in a similar way to an RR.23 In the present
meta-analysis, we combinedHRs in addition toORs. In the
Western Australia study, no HR for both AAA-related and
all-cause deaths was reported, but only an RR for all-cause
deaths could be calculated.We combined the threeHRs for
AAA-related deaths and did the three HRs and one RR
(instead of HR) for all-cause deaths. Long-term (11-year)
all-cause mortality in the Western Australia study was
available not in full-text original publication but only in
citation in the meta-analysis by Lindholt and Norman2
and the response to the comment by Lederle3 on the
meta-analysis.2 If an HR for all-cause long-term deaths
in the Western Australia study is reported, HRs in all the
four randomized controlled trials should be combined to
reassess whether or not population-based screening for
AAA reduces all-cause mortality.
The reduction in all-cause long-term mortality by
population-based screening for AAA shows a strong trend
toward significance (P for ORs  .06; P for HRs  .052)
but is very small (relative odds reduction, 0.02; relative
hazard reduction, 0.02). In the Chichester study,24 a pos-
sibly substantial increase in ruptured AAA among partici-
pants screened as normal was noted during later follow-up.
Such an increase would reduce the long-term benefit from
a single initial scan. Based on the 10-year MASS data,25 the
incremental cost per man invited to screening was £100
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effectiveness ratio of £7,600 (£5,100 to £13,000) per life
year gained. However, the incidence of ruptured abdomi-
nal aortic aneurysms in those originally screened as normal
increased noticeably after 8 years. The mortality benefit of
Table. Original data for all-cause mortality included in th
Study
Follow-
up (y) Reference
Lindholt and Normen2
Mid-term Long-term
OR (95% CI) [Nu
Chichester 5 Br J Surg 1995;
82:1066-70
1.07
(0.93-1.22
[532/3,205;
508/3228])
15 Br J Surg 2007;
94:696-701
1.00
(0.90-1.12)
[2036/2995;
2067/3045]
MASS 4 Lancet 2002;360:
1531-9
0.97
(0.93-1.02)
[3750/33,839;
3855/33,961]
7 Ann Intern Med
2007;146:
699-706
0.97
(0.93-1.02)
[3750/33,839;
3855/33,961] *
10 BMJ 2009;338:
b2307
Viborg
Country
5 BMJ 2005;330:
750
0.90
(0.82-0.99)
[939/6333;
1019/6306]
10 Eur J Vasc
Endovasc Surg
2006;32:608-
14
0.93
(0.85-1.01)
[1376/6333;
1452/6306]
†
14
Western
Australia
5 BMJ 2004;329:
1259
0.85
(0.80-0.90)
[2232/19,352;
2571/19,352]
‡
2
11 Eur J Vasc
Endovasc Surg
2008;36:167-
71
0.91
(0.88-0.95)
[7760/19,352;
8194/19,352]
‡
11 Eur J Vasc
Endovasc Surg
2008;36:620-
1; author reply
621-2
Summary estimate 0.94
(0.86-1.02)
0.94
(0.91-0.97)
P for effect .14  .0001
Model Random Fixed
P for heterogeneity .001 .12
CI, Confidence interval; HR, hazard ratio; MASS, Multicentre Aneurysm S
*Error: the values are the 4-year results.
†Error: the values are the 7-year results (Eur J Vasc Endovasc Surg 2007;34
‡Crude deaths.
¶Age standardized deaths per 100,000 in strata of 1 year to age structure o
§Data for men aged 65 to 74 years only (age matching being satisfactory fo
Error: the number of participants in the control group is not 13,975 but 1
#Risk ratio calculated by us on the basis of the data for men aged 65 to 74
**Although the P for heterogeneity was .25 (.05), Lederle3 combined st
††Although Koelemay4 stated that the effect on all-cause long-term mortal
figure was .03 (.05).
Bold entries indicate inadequate abstraction.screening for AAA is maintained up to 10 years, and costeffectiveness becomes more favorable over time. To maxi-
mize the benefit from a screening program, emphasis
should be placed on achieving a high initial rate of atten-
dance and good adherence to clinical follow-up, preventing
delays in undertaking surgery, and maintaining a low oper-
ent and present meta-analyses
Meta-analysis
[letter]3
Author reply to
Lederle [letter]3 Koelemay [letter]4 Present study
-term Long-term Long-term Long-term
deaths/participants in screening; control group] HR (95% CI)
07
-1.22)
3,205;
3228]
1.00
(0.90-1.12)
[2036/2995;
2067/3045]
1.00
(0.90-1.12)
[2036/2995;
2067/3045]
1.00
(0.90-1.12)
[2036/2995;
2067/3045]
1.01
(0.95-1.07)
97
-1.02)
33,839;
33,961]
0.96
(0.93-1.00)
[6882/33,839;
7119/33,961]
0.96
(0.93-1.00)
[6882/33,839;
7119/33,961]
0.97
(0.94-1.00)
[10,274/33,883;
10,481/33,887]
0.97
(0.95-1.00)
90
-0.99)
6333;
/6306]
0.93
(0.85-1.01)
[1376/6333;
1452/6306]
†
0.96
(0.89-1.03)
[2184/6333;
2234/6306]
0.97
(0.91-1.04)
[2931/6333;
2964/6306]
0.98
(0.93-1.03)
98
-1.04)
19,352;
9,352]
¶
0.98
(0.94-1.03)
[4719/13,970;
4768/13,957]
§
0.99
(0.94-1.04)
[4719/13,970;
4768/13,975]

0.98
(0.94-1.03)
[4719/13,970;
4768/13,957]
§
0.99
(0.96-1.02)#
97
-1.01)
0.97
(0.93-1.01)
0.97
(0.95-1.00)
††
0.98
(0.95-1.001)
0.98
(0.96-1.0001)
18 .02 .03
†† .06 .052
om** Fixed Fixed Fixed Fixed
25** .60 .80 .93 .74
ng Study; OR, odds ratio.
).
ern Australian male population aged 65 to 83 years.
sub-group).
.
nly.
ecific estimates in the random-effects model.
ed to reach statistical significance, the P for effect displayed in the originale rec
Lederle
Mid
mber of
1.
(0.93
[532/
508/
0.
(0.93
[3750/
3855/
0.
(0.82
[939/
1019
0.
(0.91
[1976/
020/1
0.
(0.93
.
Rand
.
creeni
:53-8
f West
r this
3,957
years o
udy-sp
ity failative mortality after elective surgery.25
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standingly efficient compared to established cancer screen-
ing programs. Mammographic screening is likely to reduce
breast cancer mortality. A Cochrane systematic review by
Gøtzsche and Nielsen26 showed a significant reduction in
breast cancer mortality at 13 years (RR, 0.81; 95% CI, 0.74
to 0.87; ARR, 0.7 per 1000; NNS, 1339). All-cause mor-
tality was not significantly reduced after 13 years. Fecal
occult blood test screening reduces the risk of colorectal
cancer mortality. An updated Cochrane systematic review
by Hewitson et al27 indicated that screening had a 16%
reduction in the RR of colorectal cancer mortality with
follow-up ranging from 8 to 18 years (RR 0.84, 95% CI,
0.78 to 0.90; ARR, 1.5 per 1000; NNS, 671). There was
no difference in all-cause mortality. Meanwhile, AAA
screening reduced AAA-related mortality (ARR, 4 per
1000) and showed a strong trend toward significant reduc-
tion in all-cause mortality (ARR, 5 per 1000) over control
with 10- to 15-year follow-up.
AUTHOR CONTRIBUTIONS
Conception and design: HT, TU
Analysis and interpretation: HT, TU
Data collection: SG, MM, HM
Writing article: HT
Critical revision of the article: HT, TU
Final approval of the article: HT, SG, MM, HM, TU
Statistical analysis: HT
Obtaining funding: N/A
Overall responsibility: HT, TU
REFERENCES
1. Cosford PA, Leng GC. Screening for abdominal aortic aneurysm.
Cochrane Database Syst Rev 2007;(2):CD002945.
2. Lindholt JS, Norman P. Screening for abdominal aortic aneurysm
reduces overall mortality in men. A meta-analysis of the mid- and
long-term effects of screening for abdominal aortic aneurysms. Eur J
Vasc Endovasc Surg 2008;36:167-71.
3. Lederle FA. Comment on “Screening for abdominal aortic aneurysm
reduces overall mortality in men.” Eur J Vasc Endovasc Surg 2008;36:
620-1; author reply 621-2.
4. Koelemay MJ. Comment on “Screening for abdominal aortic aneurysm
and overall mortality in men.” Eur J Vasc Endovasc Surg 2009;37:739-
40; author reply 740.
5. Takagi H, Tanabashi T, Kawai N, Kato T, Umemoto T. Abdominal
aortic aneurysm screening reduces mortality: meta-analyses of random-
ized, controlled trials. Eur J Vasc Endovasc Surg 2007;33:132-3.
6. Takagi H, Kawai N, Umemoto T. Abdominal aortic aneurysm: screen-
ing reduces all cause mortality in men. BMJ 2007;335:899.
7. Takagi H, Tanabashi T, Kawai N, Umemoto T. Regarding “Screening
for abdominal aortic aneurysm reduces both aneurysm-related and
all-cause mortality.” J Vasc Surg 2007;46:1311-2; author reply 1312.
8. Takagi H, Kawai N, Umemoto T. Regarding “Screening for abdominal
aortic aneurysm in Canada.” J Vasc Surg 2008;47:1376-7.
9. Fleming C, Whitlock EP, Beil TL, Lederle FA. Screening for abdominal
aortic aneurysm: a best-evidence systematic review for the U.S. Preven-
tive Services Task Force. Ann Intern Med 2005;142:203-11.10. Norman PE, Jamrozik K, Lawrence-Brown MM, Le MT, Spencer CA,
Tuohy RJ, et al. Population based randomised controlled trial on
impact of screening onmortality from abdominal aortic aneurysm. BMJ
2004;329:1259. Erratum in: BMJ 2005;330:596.
11. Thompson SG, Ashton HA, Gao L, Scott RA; Multicentre Aneurysm
Screening Study Group. Screening men for abdominal aortic aneurysm:
10 year mortality and cost effectiveness results from the randomised
Multicentre Aneurysm Screening Study. BMJ 2009;338:b2307.
12. Harris RP, HelfandM,Woolf SH, Lohr KN,Mulrow CD, Teutsch SM,
et al. Current methods of the US Preventive Services Task Force: a
review of the process. Am J Prev Med 2001;20(3 Suppl):21-35.
13. EggerM,Davey SmithG, SchneiderM,Minder C. Bias inmeta-analysis
detected by a simple, graphical test. BMJ 1997;315:629-34.
14. ReviewManager (RevMan) [Computer program]. Version 5.0. Copen-
hagen: The Nordic Cochrane Centre, The Cochrane Collaboration,
2008.
15. Ashton HA, Gao L, Kim LG, Druce PS, Thompson SG, Scott RA.
Fifteen-year follow-up of a randomized clinical trial of ultrasonographic
screening for abdominal aortic aneurysms. Br J Surg 2007;94:696-701.
16. Lindholt JS, Sørensen J, Søgaard R,Henneberg EW. Long-term benefit
and cost-effectiveness analysis of screening for abdominal aortic aneu-
rysms from a randomized controlled trial. Br J Surg 2010;97:826-34.
17. Scott RA, Wilson NM, Ashton HA, Kay DN. Influence of screening on
the incidence of ruptured abdominal aortic aneurysm: 5-year results of
a randomized controlled study. Br J Surg 1995;82:1066-70.
18. Lindholt JS, Juul S, Fasting H, Henneberg EW. Screening for abdom-
inal aortic aneurysms: single centre randomised controlled trial. BMJ
2005;330:750. Erratum in: BMJ 2005;331:876.
19. Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RA, et
al. The Multicentre Aneurysm Screening Study (MASS) into the effect
of abdominal aortic aneurysm screening onmortality in men: a random-
ised controlled trial. Lancet 2002;360:1531-9.
20. Mastracci TM, Cinà CS; Canadian Society for Vascular Surgery. Screen-
ing for abdominal aortic aneurysm in Canada: review and position
statement of the Canadian Society for Vascular Surgery. J Vasc Surg
2007;45:1268-76.
21. Kim LG, P Scott RA, Ashton HA, Thompson SG; Multicentre Aneu-
rysm Screening StudyGroup. A sustainedmortality benefit from screen-
ing for abdominal aortic aneurysm. Ann Intern Med 2007;146:699-
706. Erratum in: Ann Intern Med 2007;147:216.
22. Lindholt JS, Juul S, Fasting H, Henneberg EW. Preliminary ten year
results from a randomised single centre mass screening trial for abdom-
inal aortic aneurysm. Eur J Vasc Endovasc Surg 2006;32:608-14.
23. Deeks JJ, Higgins JP, Altman DG, editors. Chapter 9: Analysing data
and undertaking meta-analyses. In: Higgins JP, Green S, editors. Co-
chrane Handbook for Systematic Reviews of Interventions Version
5.0.1 (updated September 2008). Oxford, UK: The Cochrane Collab-
oration, 2008. Available from www.cochrane-handbook.org. Accessed
July 1, 2009.
24. Hafez H, Druce PS, Ashton HA. Abdominal aortic aneurysm develop-
ment in men following a “normal” aortic ultrasound scan. Eur J Vasc
Endovasc Surg 2008;36:553-8.
25. Thompson SG, Ashton HA, Gao L, Scott RA; Multicentre Aneurysm
Screening Study Group. Screening men for abdominal aortic aneurysm:
10 year mortality and cost effectiveness results from the randomised
Multicentre Aneurysm Screening Study. BMJ 2009;338:b2307.
26. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammog-
raphy. Cochrane Database Syst Rev 2009;(4):CD001877.
27. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane
systematic review of colorectal cancer screening using the fecal occult
blood test (hemoccult): an update. Am J Gastroenterol 2008;103:
1541-9.Submitted Aug 5, 2009; accepted Feb 25, 2010.
